α-[1-(4'-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(morpholinomethyl)acetohydroxamic acid | 344743-27-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: α-[1-(4'-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(morpholinomethyl)acetohydroxamic acid
• 英文别名: 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-hydroxy-N-(morpholin-4-ylmethyl)acetamide
• CAS: 344743-27-7
• 化学式: C₂₄H₂₆ClN₃O₅
• 分子量: 471.941
• InChiKey: DZBKAIKDXAKVRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  奥沙美辛 、 聚合甲醛 、 吗啉 生成 α-[1-(4'-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(morpholinomethyl)acetohydroxamic acid
  参考文献：
  名称：

  SLOAN, K. B.;LITTLE, R.

  摘要：

  DOI：

文献信息

• Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them
  申请人：Merck & Co., Inc.

  公开号：EP0039051A2

  公开（公告）日：1981-11-04

  Novel prodrug forms of known non-steroidal anti-inflammatory agents and a process for preparing them are disclosed, said prodrugs having the structural formula wherein is the acyl residue of a non-steroidal anti-inflammatory agent containing a carboxylic acid function; R1 and R2 each represent alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, alkynyl, aralkyl, alkaryl aralkenyl, aralkynyl, alkenylaryl, and alkynylaryl, and substituted derivatives of the above groups; or R, and R2 are combined so that -NR1 R2 together represent the residue of a heterocyclic compound containing one secondary nitrogen atom; R3 is hydrogen, R1 -CH2OCOR'1, -CH2ONO2, pyridyl, furyl, cyano, carbamyl, alkyl carbamyl, and dialkylcarbamyl; R', is any radical encompassed by the definition of R1 above; or a non-toxic pharmaceutically acceptable acid addition salt or oxide thereof. These compounds are characterized as being more readily bioavailable, less irritating to topical and gastric mucosal membranes, and more permeable through topical membranes than are the "parent" nonsteroidal anti-inflammatory slcugs from which they are derived.

  本发明公开了已知非甾体抗炎剂的新型原药及其制备方法，所述原药的结构式为 其中 是含有羧酸官能团的非甾体抗炎剂的酰基残基；R1 和 R2 各自代表烷基、烯基、芳基、环烷基、环烯基、炔基、芳烷基、烷芳基芳烯基、芳炔基、烯芳基和炔芳基，以及上述基团的取代衍生物；或者 R 和 R2 组合在一起，使 -NR1 R2 共同代表含有一个仲氮原子的杂环化合物的残基；R3 是氢、R1 -CH2OCOR'1、-CH2ONO2、吡啶基、呋喃基、氰基、氨甲酰基、烷基氨甲酰基和二烷基氨甲酰基；R'是上述 R1 定义所包含的任何基团；或其无毒性的药学上可接受的酸加成盐或氧化物。 与 "母体 "非甾体抗炎药相比，这些化合物的特点是更易于生物利用，对局部和胃黏膜的刺激性更小，通过局部薄膜的渗透性更好。
• US4412994A
  申请人：——

  公开号：US4412994A

  公开（公告）日：1983-11-01